May 15 (Reuters) - The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drug sold by AstraZeneca, Johnson & Johnson and Eli Lilly in partnership with Boehringer Ingleheim may a cause dangerously high levels of blood acids that could require hospitalization.
The drugs belong to a class known as SGLT2 inhibitors that work by causing blood sugar to be secreted in the urine. They include AstraZeneca's Farxiga (dapagliflozin), J&J's Invokana (canagliflozin) and Jardiance (embagliflozin) from Lilly and Boehringer.
The FDA in a warning on its website said the medicines may lead to ketoacidosis, a serious condition where the body produces high levels of blood acids called ketones. (Reporting by Bill Berkrot; Editing by Jeffrey Benkoe)